Coronavirus Disease-2019 Pandemic Effects on Patient Decisions Regarding Clinical Trial Participation

-
imageNo abstract available

from Anesthesia & Analgesia - Latest Articles https://ift.tt/6hWGXvS
via IFTTT

Comments

Post a Comment

Latest Updates

Popular posts from this blog

Associations Between Nonanemic Iron Deficiency and Postoperative Outcomes in Cardiac Surgery: A Systematic Review and Meta-Analysis

-
Image
BACKGROUND: Preoperative screening for iron deficiency is a part of patient blood management protocols. This systematic review, meta-analysis, and meta-regression reviews the association between nonanemic iron deficiency and postoperative outcomes in patients undergoing cardiac surgery. We aimed to determine whether preoperative screening for nonanemic iron deficiency should be recommended in patients undergoing cardiac surgery. METHODS: Electronic databases MEDLINE (Ovid), Embase (Ovid), and Scopus were searched from inception until December 9, 2022. Studies were considered for inclusion if they (1) used an observational study design; (2) enrolled adult patients undergoing cardiac surgery; and (3) included an iron-deficient and iron-replete group, defined using serum ferritin and/or transferrin saturation. The primary outcome was the length of acute hospital stay. Secondary outcomes included length of intensive care unit stay, requirement for allogeneic red blood cell transfusion, num...
Read more

Continuous vs. Bolus Norepinephrine for Post-Induction Hypotension

-
Continuous vs. Bolus Norepinephrine for Post-Induction Hypotension Continuous vs. Bolus Norepinephrine for Post-Induction Hypotension: A Landmark Trial Key Takeaway: Continuous infusion of norepinephrine offers no significant advantage over manual bolus administration in reducing post-induction hypotension in low-to-moderate risk noncardiac surgery patients, according to a randomized trial in the British Journal of Anaesthesia . Study Design Participants: 276 patients (261 analyzed) undergoing elective noncardiac surgery Interventions: Randomized to continuous infusion (target: 0.05 µg/kg/min) or manual boluses (10 µg) Monitoring: Intermittent oscillometric BP + blinded continuous finger-cuff monitoring Primary Endpoint: Area under MAP Key Findings Metric Continuous Infusion Bolus Administration Area under MA...
Read more

Danavorexton (TAK-925): A Promising Breakthrough in Combating Opioid-Induced Respiratory Depression

-
Danavorexton (TAK-925): A Promising Breakthrough in Combating Opioid-Induced Respiratory Depression Danavorexton (TAK-925): A Promising Breakthrough in Combating Opioid-Induced Respiratory Depression Opioids remain a cornerstone of pain management in clinical settings, yet their use is shadowed by life-threatening side effects, including respiratory depression and excessive sedation. A recent podcast episode from Anesthesiology ’s featured author series highlights a groundbreaking solution: danavorexton (TAK-925) , an orexin receptor 2 agonist that could revolutionize how we manage opioid-related complications. What Is Danavorexton (TAK-925)? Danavorexton is a selective agonist of the orexin-2 receptor (OX2R), a key player in regulating wakefulness and respiration. Orexins (also known as hypocretins) are neuropeptides produced in the hypothalamus that activate OX1R and OX2R receptors, influencing arousal, appetite, and...
Read more